Branebrutinib

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameBranebrutinib
Drug Alias NameBMS-986195
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsImmune System DiseasesLupus Erythematosus, SystemicDermatitis, Atopic +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[13] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb Srlcompany
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicDermatitis, AtopicSjogren's Syndrome +[4] 
Inactive IndicationsImmune System Diseases

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank